Minimed Group Inc's Comment on Sales, Marketing and Customers
The company provides products and services for people with diabetes worldwide, focusing on individuals requiring intensive insulin therapy, including all people with Type 1 Diabetes and some with Type 2 Diabetes. Its offerings include insulin delivery devices such as insulin pumps and pens, continuous glucose monitors, consumables, supplies, and related software and services. The estimated market size for these diabetes technologies exceeds $19 billion based on revenue data through February 2026. In the United States, distribution primarily occurs through the Durable Medical Equipment channel, with a smaller portion through pharmacies. The market is projected to grow at a compound annual growth rate above 10% from 2026 through at least 2030. Primary medical specialists prescribing the company’s products include endocrinologists, diabetologists, nurse practitioners, physician assistants, and primary care physicians. The company aligns its health outcomes with guidelines from the European Association for the Study of Diabetes and the American Diabetes Association to support improved glycemic control and reduce the burden of diabetes management for users and caregivers. Customers and markets mentioned in filings include Seagrove Partners.
Minimed Group Inc’s Comment on Sales, Marketing and Customers
The company provides products and services for people with diabetes worldwide, focusing on individuals requiring intensive insulin therapy, including all people with Type 1 Diabetes and some with Type 2 Diabetes. Its offerings include insulin delivery devices such as insulin pumps and pens, continuous glucose monitors, consumables, supplies, and related software and services. The estimated market size for these diabetes technologies exceeds $19 billion based on revenue data through February 2026. In the United States, distribution primarily occurs through the Durable Medical Equipment channel, with a smaller portion through pharmacies. The market is projected to grow at a compound annual growth rate above 10% from 2026 through at least 2030. Primary medical specialists prescribing the company’s products include endocrinologists, diabetologists, nurse practitioners, physician assistants, and primary care physicians. The company aligns its health outcomes with guidelines from the European Association for the Study of Diabetes and the American Diabetes Association to support improved glycemic control and reduce the burden of diabetes management for users and caregivers. Customers and markets mentioned in filings include Seagrove Partners.
Sources:
Minimed Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Minimed Group Inc’s corporate clients.
For your research, we’ve provided 9 tables on Minimed Group Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
28.47 %